INST GUSTAVE ROUSSY IGR has a total of 25 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2002. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are FEMALON S P R L, PACYLEX PHARMACEUTICALS INC and TULLY TIMOTHY P.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 13 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | Australia | 2 | |
#4 | France | 2 | |
#5 | Canada | 1 | |
#6 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Machines |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Measuring microorganism processes | |
#5 | Peptides | |
#6 | Diagnosis and surgery | |
#7 | Microorganisms | |
#8 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Raslova Hana | 5 |
#2 | Vainchenker William | 5 |
#3 | Zitvogel Laurence | 5 |
#4 | Bluteau Dominique | 5 |
#5 | Vozenin Marie Catherine | 4 |
#6 | Peronneau Pierre | 4 |
#7 | Bourhis Jean | 4 |
#8 | Deutsch Eric | 4 |
#9 | Lassau Nathalie | 4 |
#10 | Triebel Frederic | 3 |
Publication | Filing date | Title |
---|---|---|
EP2850414A1 | Characterization of biological tissues at a cellular level using red and far-red fluorescent dyes | |
WO2013139479A1 | New diagnostic markers of specific chronic myelomonocytic leukemia (cmml) | |
EP2708605A1 | ANKRD26 as a marker for diagnosis of thrombocytopenias | |
EP2492687A1 | MYH10 as a new diagnostic marker of pathologies resulting from RUNX1 inactivation | |
EP2426216A1 | Prognostic and/or predictive biomarkers and biological applications thereof | |
EP2371369A1 | EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer | |
FR2850385A1 | Echogenic microparticles, in particular as a contrast agent for ultrasonic exploration and / or as embols for ultrasonic detection | |
FR2844452A1 | Modulating dendritic cell activity, e.g. for treatment of viral infections, NK-sensitive tumors or autoimmune diseases, using inhibitors or specific tyrosine kinases, e.g. c-abl, bcr/abl and c-kit |